![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 1,2-dimethylhydrazine | decreases expression | ISO | RGD:1314488 | 6480464 | 1, 2-Dimethylhydrazine results in decreased expression of CYP2S1 mRNA | CTD | PMID:22206623 | 17alpha-ethynylestradiol | affects expression | ISO | RGD:1314488 | 6480464 | Ethinyl Estradiol affects the expression of CYP2S1 mRNA | CTD | PMID:17555576 | 17alpha-ethynylestradiol | multiple interactions | ISO | RGD:1314488 | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of CYP2S1 mRNA | CTD | PMID:17942748 | 17alpha-ethynylestradiol | increases expression | ISO | RGD:1314488 | 6480464 | Ethinyl Estradiol results in increased expression of CYP2S1 mRNA | CTD | PMID:17942748 | 17beta-estradiol | increases expression | ISO | RGD:1314487 | 6480464 | Estradiol results in increased expression of CYP2S1 mRNA | CTD | PMID:21632981 | 17beta-estradiol | multiple interactions | ISO | RGD:1314487 | 6480464 | [Estradiol co-treated with TGFB1 protein] results in decreased expression of CYP2S1 mRNA | CTD | PMID:30165855 | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:1314488 | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of CYP2S1 mRNA more ... | CTD | PMID:17277313 more ... | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:1314488 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of CYP2S1 mRNA | CTD | PMID:17277313 more ... | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:1314487 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of CYP2S1 mRNA | CTD | PMID:22344700 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | RGD:1314488 | 6480464 | Tetrachlorodibenzodioxin affects the expression of CYP2S1 mRNA | CTD | PMID:21570461 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:1314488 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of CYP2S1 mRNA | CTD | PMID:19770486 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of CYP2S1 mRNA | CTD | PMID:19883719 | 2-hydroxypropanoic acid | affects expression | ISO | RGD:1314487 | 6480464 | Lactic Acid affects the expression of CYP2S1 mRNA | CTD | PMID:30851411 | 2-naphthylamine | increases reduction | ISO | RGD:1314487 | 6480464 | CYP2S1 protein results in increased reduction of 2-Naphthylamine analog | CTD | PMID:23682735 | 3,3',4,4',5-pentachlorobiphenyl | increases expression | ISO | RGD:1314488 | 6480464 | 3 more ... | CTD | PMID:23994337 | 3-methylcholanthrene | increases expression | EXP | | 6480464 | Methylcholanthrene results in increased expression of CYP2S1 mRNA | CTD | PMID:19883719 | 4,4'-sulfonyldiphenol | increases expression | ISO | RGD:1314488 | 6480464 | bis(4-hydroxyphenyl)sulfone results in increased expression of CYP2S1 mRNA | CTD | PMID:30951980 | 4-hydroxyphenyl retinamide | decreases expression | ISO | RGD:1314488 | 6480464 | Fenretinide results in decreased expression of CYP2S1 mRNA | CTD | PMID:28973697 | 5-fluorouracil | affects expression | ISO | RGD:1314488 | 6480464 | Fluorouracil affects the expression of CYP2S1 mRNA | CTD | PMID:20421339 | 7,12-dimethyltetraphene | multiple interactions | ISO | RGD:1314487 | 6480464 | [CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of 9 more ... | CTD | PMID:19713358 | actinomycin D | multiple interactions | ISO | RGD:1314488 | 6480464 | Dactinomycin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP2S1 mRNA] | CTD | PMID:17277313 | aflatoxin B1 | multiple interactions | ISO | RGD:1314487 | 6480464 | [CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of Aflatoxin B1, [CYP2S1 protein co-treated with Hydrogen Peroxide] results in increased oxidation of Aflatoxin B1 | CTD | PMID:19713358 | aflatoxin B1 | increases expression | ISO | RGD:1314487 | 6480464 | Aflatoxin B1 results in increased expression of CYP2S1 mRNA | CTD | PMID:22100608 | all-trans-retinoic acid | multiple interactions | ISO | RGD:1314487 | 6480464 | [CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of Tretinoin, [CYP2S1 protein co-treated with Hydrogen Peroxide] results in increased oxidation of Tretinoin | CTD | PMID:19713358 | all-trans-retinoic acid | increases expression | ISO | RGD:1314487 | 6480464 | Tretinoin results in increased expression of CYP2S1 mRNA | CTD | PMID:12711469, PMID:16985168 | all-trans-retinoic acid | increases metabolic processing | ISO | RGD:1314487 | 6480464 | CYP2S1 protein results in increased metabolism of Tretinoin | CTD | PMID:12711469 | all-trans-retinoic acid | affects expression | ISO | RGD:1314488 | 6480464 | Tretinoin affects the expression of CYP2S1 mRNA | CTD | PMID:20421339 | all-trans-retinoic acid | affects metabolic processing | ISO | RGD:1314487 | 6480464 | CYP2S1 protein affects the metabolism of Tretinoin | CTD | PMID:16054184 | antirheumatic drug | decreases expression | ISO | RGD:1314487 | 6480464 | Antirheumatic Agents results in decreased expression of CYP2S1 mRNA | CTD | PMID:24449571 | aristolochic acid A | increases expression | ISO | RGD:1314487 | 6480464 | aristolochic acid I results in increased expression of CYP2S1 mRNA | CTD | PMID:33212167 | azathioprine | increases expression | ISO | RGD:1314487 | 6480464 | Azathioprine results in increased expression of CYP2S1 mRNA | CTD | PMID:22623647 | beclomethasone | decreases expression | ISO | RGD:1314487 | 6480464 | Beclomethasone results in decreased expression of CYP2S1 mRNA | CTD | PMID:22155357 | benzo[a]pyrene | multiple interactions | ISO | RGD:1314487 | 6480464 | [[CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of Benzo(a)pyrene] which results in increased abundance of benzo(a)pyrene-1 more ... | CTD | PMID:19713358 | benzo[a]pyrene | increases expression | ISO | RGD:1314488 | 6480464 | Benzo(a)pyrene results in increased expression of CYP2S1 mRNA | CTD | PMID:21995607 | benzo[a]pyrene | increases expression | ISO | RGD:1314487 | 6480464 | Benzo(a)pyrene results in increased expression of CYP2S1 mRNA | CTD | PMID:21632981 more ... | benzo[a]pyrene | multiple interactions | ISO | RGD:1314488 | 6480464 | AHR affects the reaction [Benzo(a)pyrene results in increased expression of CYP2S1 mRNA] more ... | CTD | PMID:21995607, PMID:22228805 | benzo[a]pyrene | decreases expression | ISO | RGD:1314488 | 6480464 | Benzo(a)pyrene results in decreased expression of CYP2S1 mRNA | CTD | PMID:19770486 | benzo[a]pyrene diol epoxide I | increases expression | ISO | RGD:1314487 | 6480464 | 7 more ... | CTD | PMID:20382639 | Benzo[a]pyrene-7,8-diol | multiple interactions | ISO | RGD:1314487 | 6480464 | [[CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of benzo(a)pyrene 7 more ... | CTD | PMID:19713358 | beta-naphthoflavone | increases expression | ISO | RGD:1314488 | 6480464 | beta-Naphthoflavone results in increased expression of CYP2S1 mRNA | CTD | PMID:23994337 | biphenyl-4-amine | increases reduction | ISO | RGD:1314487 | 6480464 | CYP2S1 protein results in increased reduction of 4-biphenylamine analog | CTD | PMID:23682735 | bis(2-chloroethyl) sulfide | increases expression | ISO | RGD:1314487 | 6480464 | Mustard Gas results in increased expression of CYP2S1 mRNA | CTD | PMID:25102026 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of CYP2S1 mRNA | CTD | PMID:25181051 | bisphenol A | increases expression | ISO | RGD:1314488 | 6480464 | bisphenol A results in increased expression of CYP2S1 mRNA | CTD | PMID:34585602 | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of CYP2S1 mRNA | CTD | PMID:34947998 | bisphenol A | decreases expression | ISO | RGD:1314487 | 6480464 | bisphenol A results in decreased expression of CYP2S1 mRNA | CTD | PMID:31715268 | butanal | decreases expression | ISO | RGD:1314487 | 6480464 | butyraldehyde results in decreased expression of CYP2S1 mRNA | CTD | PMID:26079696 | cadmium dichloride | increases expression | EXP | | 6480464 | Cadmium Chloride results in increased expression of CYP2S1 mRNA | CTD | PMID:33453195 | calcitriol | decreases expression | ISO | RGD:1314487 | 6480464 | Calcitriol results in decreased expression of CYP2S1 mRNA | CTD | PMID:16002434 | calcitriol | multiple interactions | ISO | RGD:1314487 | 6480464 | [Testosterone co-treated with Calcitriol] results in increased expression of CYP2S1 mRNA | CTD | PMID:21592394 | calcitriol | increases expression | ISO | RGD:1314487 | 6480464 | Calcitriol results in increased expression of CYP2S1 mRNA | CTD | PMID:21592394, PMID:27107558 | carbon nanotube | decreases expression | ISO | RGD:1314488 | 6480464 | Nanotubes more ... | CTD | PMID:25554681 | cisplatin | increases expression | ISO | RGD:1314487 | 6480464 | Cisplatin results in increased expression of CYP2S1 mRNA | CTD | PMID:27392435 | cisplatin | multiple interactions | ISO | RGD:1314487 | 6480464 | [Cisplatin co-treated with jinfukang] results in increased expression of CYP2S1 mRNA | CTD | PMID:27392435 | cortisol | decreases expression | ISO | RGD:1314487 | 6480464 | Hydrocortisone results in decreased expression of CYP2S1 mRNA | CTD | PMID:22155357 | cumene hydroperoxide | multiple interactions | ISO | RGD:1314487 | 6480464 | [[CYP2S1 protein co-treated with cumene hydroperoxide] results in increased oxidation of benzo(a)pyrene 7 more ... | CTD | PMID:19713358 | Cuprizon | decreases expression | EXP | | 6480464 | Cuprizone results in decreased expression of CYP2S1 mRNA | CTD | PMID:26577399 | cyclosporin A | decreases expression | ISO | RGD:1314488 | 6480464 | Cyclosporine results in decreased expression of CYP2S1 mRNA | CTD | PMID:19770486 | cyclosporin A | increases expression | ISO | RGD:1314487 | 6480464 | Cyclosporine results in increased expression of CYP2S1 mRNA | CTD | PMID:25562108 | dexamethasone | decreases expression | ISO | RGD:1314487 | 6480464 | Dexamethasone results in decreased expression of CYP2S1 mRNA, Dexamethasone results in decreased expression of CYP2S1 protein | CTD | PMID:22155357 | dexamethasone | multiple interactions | ISO | RGD:1314487 | 6480464 | NR3C1 protein promotes the reaction [Dexamethasone results in decreased expression of CYP2S1 mRNA] more ... | CTD | PMID:22155357 | dextran sulfate | multiple interactions | ISO | RGD:1314488 | 6480464 | [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2S1 mRNA | CTD | PMID:29950665 | diazinon | increases methylation | ISO | RGD:1314487 | 6480464 | Diazinon results in increased methylation of CYP2S1 gene | CTD | PMID:22964155 | dibenz[a,h]anthracene | decreases expression | ISO | RGD:1314488 | 6480464 | 1 more ... | CTD | PMID:26377693 | dioxygen | multiple interactions | ISO | RGD:1314487 | 6480464 | Oxygen affects the reaction [CYP2S1 protein results in increased reduction of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole metabolite] | CTD | PMID:23682735 | disodium selenite | decreases expression | ISO | RGD:1314487 | 6480464 | Sodium Selenite results in decreased expression of CYP2S1 mRNA | CTD | PMID:18175754 | dorsomorphin | multiple interactions | ISO | RGD:1314487 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP2S1 mRNA | CTD | PMID:27188386 | entinostat | multiple interactions | ISO | RGD:1314487 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP2S1 mRNA | CTD | PMID:27188386 | entinostat | increases expression | ISO | RGD:1314487 | 6480464 | entinostat results in increased expression of CYP2S1 mRNA | CTD | PMID:26272509 | etoposide | decreases expression | ISO | RGD:1314488 | 6480464 | Etoposide results in decreased expression of CYP2S1 mRNA | CTD | PMID:25270620 | flunisolide | decreases expression | ISO | RGD:1314487 | 6480464 | flunisolide results in decreased expression of CYP2S1 mRNA | CTD | PMID:22155357 | genistein | increases expression | ISO | RGD:1314488 | 6480464 | Genistein results in increased expression of CYP2S1 mRNA | CTD | PMID:32186404 | hydrogen peroxide | multiple interactions | ISO | RGD:1314487 | 6480464 | [[CYP2S1 protein co-treated with Hydrogen Peroxide] results in increased oxidation of benzo(a)pyrene 7 more ... | CTD | PMID:19713358 | hydroxylamine | multiple interactions | ISO | RGD:1314487 | 6480464 | [CYP2S1 protein results in increased reduction of Hydroxylamine] which results in increased chemical synthesis of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole | CTD | PMID:22734839 | hydroxylamine | increases reduction | ISO | RGD:1314487 | 6480464 | CYP2S1 protein results in increased reduction of Hydroxylamine | CTD | PMID:22734839 | ivermectin | decreases expression | ISO | RGD:1314487 | 6480464 | Ivermectin results in decreased expression of CYP2S1 protein | CTD | PMID:32959892 | methoxyacetic acid | affects expression | ISO | RGD:1314488 | 6480464 | methoxyacetic acid affects the expression of CYP2S1 mRNA | CTD | PMID:20421339 | Monobutylphthalate | affects expression | ISO | RGD:1314488 | 6480464 | monobutyl phthalate affects the expression of CYP2S1 mRNA | CTD | PMID:20421339 | naphthalene | affects metabolic processing | ISO | RGD:1314487 | 6480464 | CYP2S1 protein affects the metabolism of naphthalene | CTD | PMID:16054184 | obeticholic acid | decreases expression | ISO | RGD:1314487 | 6480464 | obeticholic acid results in decreased expression of CYP2S1 mRNA | CTD | PMID:27939613 | ozone | decreases expression | ISO | RGD:1314488 | 6480464 | Ozone results in decreased expression of CYP2S1 mRNA | CTD | PMID:12763052 | ozone | multiple interactions | ISO | RGD:1314488 | 6480464 | [Air Pollutants results in increased abundance of Ozone] which results in decreased expression of CYP2S1 mRNA | CTD | PMID:34911549 | paracetamol | decreases expression | ISO | RGD:1314488 | 6480464 | Acetaminophen results in decreased expression of CYP2S1 mRNA | CTD | PMID:17585979 | paracetamol | increases expression | EXP | | 6480464 | Acetaminophen results in increased expression of CYP2S1 mRNA | CTD | PMID:33387578 | perfluorooctanoic acid | increases expression | ISO | RGD:1314487 | 6480464 | perfluorooctanoic acid results in increased expression of CYP2S1 protein | CTD | PMID:26879310 | pirinixic acid | decreases expression | ISO | RGD:1314488 | 6480464 | pirinixic acid results in decreased expression of CYP2S1 mRNA | CTD | PMID:17426115 | pirinixic acid | multiple interactions | ISO | RGD:1314488 | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of CYP2S1 mRNA | CTD | PMID:19710929 | prednisolone | decreases expression | ISO | RGD:1314487 | 6480464 | Prednisolone results in decreased expression of CYP2S1 mRNA | CTD | PMID:22155357 | quercetin | increases expression | ISO | RGD:1314487 | 6480464 | Quercetin results in increased expression of CYP2S1 mRNA | CTD | PMID:21632981 | rac-lactic acid | affects expression | ISO | RGD:1314487 | 6480464 | Lactic Acid affects the expression of CYP2S1 mRNA | CTD | PMID:30851411 | rifampicin | multiple interactions | ISO | RGD:1314487 | 6480464 | [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2S1 mRNA | CTD | PMID:21127053 | SB 431542 | multiple interactions | ISO | RGD:1314487 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP2S1 mRNA | CTD | PMID:27188386 | silicon dioxide | decreases expression | ISO | RGD:1314487 | 6480464 | Silicon Dioxide analog results in decreased expression of CYP2S1 mRNA | CTD | PMID:25895662 | silver atom | increases expression | ISO | RGD:1314488 | 6480464 | Silver results in increased expression of CYP2S1 mRNA | CTD | PMID:27131904 | silver(0) | increases expression | ISO | RGD:1314488 | 6480464 | Silver results in increased expression of CYP2S1 mRNA | CTD | PMID:27131904 | sodium arsenite | increases expression | ISO | RGD:1314487 | 6480464 | sodium arsenite results in increased expression of CYP2S1 mRNA | CTD | PMID:29301061 | succimer | multiple interactions | ISO | RGD:1314488 | 6480464 | [Succimer co-treated with Magnetite Nanoparticles] results in increased expression of CYP2S1 mRNA | CTD | PMID:26378955 | tamoxifen | affects expression | ISO | RGD:1314488 | 6480464 | Tamoxifen affects the expression of CYP2S1 mRNA | CTD | PMID:17555576 | testosterone | multiple interactions | ISO | RGD:1314487 | 6480464 | [Testosterone co-treated with Calcitriol] results in increased expression of CYP2S1 mRNA | CTD | PMID:21592394 | testosterone | increases expression | ISO | RGD:1314487 | 6480464 | Testosterone results in increased expression of CYP2S1 mRNA | CTD | PMID:21592394 | titanium dioxide | affects expression | ISO | RGD:1314488 | 6480464 | titanium dioxide affects the expression of CYP2S1 mRNA | CTD | PMID:23557971 | titanium dioxide | multiple interactions | ISO | RGD:1314488 | 6480464 | [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2S1 mRNA | CTD | PMID:29950665 | triamcinolone acetonide | decreases expression | ISO | RGD:1314487 | 6480464 | Triamcinolone Acetonide results in decreased expression of CYP2S1 mRNA | CTD | PMID:22155357 | tributylstannane | increases expression | ISO | RGD:1314488 | 6480464 | tributyltin results in increased expression of CYP2S1 mRNA | CTD | PMID:31939706 | trichostatin A | multiple interactions | ISO | RGD:1314487 | 6480464 | trichostatin A inhibits the reaction [Dexamethasone results in decreased expression of CYP2S1 mRNA] | CTD | PMID:22155357 | tris(2-butoxyethyl) phosphate | affects expression | ISO | RGD:1314487 | 6480464 | tris(2-butoxyethyl) phosphate affects the expression of CYP2S1 mRNA | CTD | PMID:29024780 | valproic acid | affects expression | ISO | RGD:1314488 | 6480464 | Valproic Acid affects the expression of CYP2S1 mRNA | CTD | PMID:20421339 | valproic acid | increases expression | ISO | RGD:1314488 | 6480464 | Valproic Acid results in increased expression of CYP2S1 mRNA | CTD | PMID:21427059 | valproic acid | increases expression | ISO | RGD:1314487 | 6480464 | Valproic Acid results in increased expression of CYP2S1 mRNA | CTD | PMID:23527032 | |